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Physio4FMD: protocol for a multicentre
randomised controlled trial of specialist
physiotherapy for functional motor disorder
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Rachael Hunter3,4, Jonathan Marsden6, Louise Marston3,4 , Hayley Noble1 , Markus Reuber7 ,
Mark J. Edwards1 and on behalf of the Physio4FMD Collaborative Group
Abstract
Background: Patients with functional motor disorder (FMD) experience persistent and disabling neurological
symptoms such as weakness, tremor, dystonia and disordered gait. Physiotherapy is usually considered an
important part of treatment; however, sufficiently-powered controlled studies are lacking. Here we present the
protocol of a randomised controlled trial (RCT) that aims to evaluate the clinical and cost effectiveness of a
specialist physiotherapy programme for FMD.
Methods/design: The trial is a pragmatic, multicentre, single blind parallel arm randomised controlled trial (RCT).
264 Adults with a clinically definite diagnosis of FMD will be recruited from neurology clinics and randomised to
receive either the trial intervention (a specialist physiotherapy protocol) or treatment as usual control (referral to a
community physiotherapy service suitable for people with neurological symptoms). Participants will be followed up
at 6 and 12 months. The primary outcome is the Physical Function domain of the Short Form 36 questionnaire at
12 months. Secondary domains of measurement will include participant perception of change, mobility, health-
related quality of life, health service utilisation, anxiety and depression. Health economic analysis will evaluate the
cost impact of trial and control interventions from a health and social care perspective as well as societal
perspective.
Discussion: This trial will be the first adequately-powered RCT of physical-based rehabilitation for FMD.
Trial registration: International Standard Randomised Controlled Trials Number ISRCTN56136713. Registered 27
March 2018.
Keywords: Physiotherapy, Physical therapy, Functional, Functional motor disorder, Conversion disorder,
Psychogenic, Randomised controlled trial, Clinical trial
Background
Functional motor disorder (FMD) can be defined as
neurological symptoms affecting movement that are
caused by loss of control or agency over movement, rather
than a structural disease process. FMD is the motor-
dominant variant of functional neurological disorder (also
known as conversion disorder) [1]. Typical presentations
of FMD include weakness, tremor, jerks, dystonia, gait
disorder, or a combination of these symptoms. Most pa-
tients also experience non-motor functional neurological
symptoms, such as sensory disturbance, memory com-
plaints, pain, fatigue or dissociative seizures [1]. It is also
common for patients with FMD to have comorbid health
problems such as neurological disease [2, 3]. FMD is often
described as a condition at the interface between neur-
ology and psychiatry.
The incidence of FMD is reported to be in the range
of 4 to 12 per 100,000 [4], making it similar in incidence
to multiple sclerosis and Parkinson’s disease. The long-
term outcome is variable but often poor. A systematic
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review of long term follow up studies found that
approximately 40% of patients were the same or worse
at an average of 7 years and the majority of patients
remained symptomatic [5]. However, little is known
about the outcome of patients who receive timely spe-
cialist interventions.
In recent years, specialist physiotherapy has emerged as a
promising treatment for FMD [6]. A number of cohort
studies report positive results from physical interventions
that are based on a biopsychosocial understanding of FMD
and encompass psychosocial therapeutic elements [7–10].
The first controlled trial of physical-based rehabilitation for
FMD, published in 2014, compared an intervention group
with patients waiting for treatment [11]. In this study 60
patients with a functional gait disorder were randomised to
a 3-week inpatient physical rehabilitation programme or a
4-week waiting list. Group comparisons demonstrated a
statistically significant improvement with treatment across
a range of physical and quality of life outcome measures.
The mean differences immediately after the intervention
were 6.9 units in the Functional Mobility Scale (15 point
range), 8.4 Functional Independence Scale units (108 point
range), and 11.7 SF12 Physical Domain units (maximum
score 100). Post intervention improvement was sustained
at 12months follow up, except for the SF12 Mental Health
domain which showed an immediate treatment effect of
6.7 units (100 point range) but was no longer statistically
different from baseline scores at 12months.
Our group has recently completed a single centre, ran-
domised feasibility trial of specialist physiotherapy for
FMD [12]. The intervention was based on a consensus
recommendation paper describing physiotherapy for
FMD [13] and had been previously tested in a small pro-
spective cohort study (n = 47) [9]. This intervention was
developed using a novel “movement retraining” model,
harnessing and making explicit the internal inconsisten-
cies seen in FMD which are used to make the diagnosis.
For instance, an inability to carry out volitional move-
ments (e.g. active ankle dorsiflexion) with retained ability
to carry out movements of the same muscle groups in a
different context (e.g. retained ability to activate dorsi-
flexor muscles by standing on their heels). The feasibility
trial randomised 60 patients to either our specific specia-
lised physiotherapy protocol for FMD or a treatment as
usual control (consisting of referral to standard commu-
nity neuro-physiotherapy). Participants were followed up
at 6 months. The intervention was considered unsuitable
for people whose primary problem (above motor symp-
toms) was pain, fatigue or dissociative seizures, and such
patients were excluded from the study. We also excluded
people who had psychiatric comorbidity (such as anxiety
or depression) that was deemed to require assessment
and treatment before starting physiotherapy. 32% of pa-
tients with FMD seen in the recruiting neurology clinics
met the inclusion criteria. 90% of this group consented
to participate in the trial and only 5% were lost to follow
up. Participants rated the intervention as highly
acceptable.
As part of the feasibility trial we tested a range of
physical, mental health and quality of life outcome mea-
sures. At 6 month follow up, the intervention group
scored higher on measures of physical function but there
were no differences in scores of mental health. The
Short Form 36 (SF36) Physical Function domain showed
a mean difference between groups of 19.8 (95% CI 10.2,
29.5, Cohen’s d = 0.7), after adjusting for baseline scores.
In a patient-rated 5-point Likert scale of impression of
change, 72% of the intervention group rated their symp-
toms as improved at 6 months, compared to 18% in the
control group. These promising results highlight the im-
portance of progressing this research and conducting an
adequately powered randomised trial.
In summary, there are a number of small studies
showing promise that specialist physiotherapy is effective
for people with FMD, however, there is a lack of evi-
dence from adequately-powered randomised controlled
trials (RCTs). Here we report the protocol for a RCT of
specialist physiotherapy for functional motor disorder
(Physio4FMD). In work leading up to this research, we
developed consensus recommendations for physiother-
apy treatment [13]. The trial intervention was based on
these recommendations and further developed during
the course of our clinical practice and clinical research
[9, 12]. In line with MRC guidelines for evaluating com-
plex interventions [14], we have completed proof of
principle in a feasibility trial, obtaining preliminary evi-
dence for efficacy in a small sample. The next stage is to
evaluate the clinical and cost effectiveness, as well as
generalisability of the intervention in a pragmatic multi-
centre RCT.
Aims and objectives
The overall aim of the Physio4FMD trial is to evaluate
the clinical and cost effectiveness of a specialist physio-
therapy protocol for FMD, compared to treatment as
usual within a pragmatic, multicentre RCT. The primary
objective is to evaluate the effectiveness of specialist
physiotherapy compared to treatment as usual in redu-
cing disability, measured by the Physical Function do-
main of the SF36 at 12 months post randomisation.
The secondary objectives are to evaluate the effective-
ness of the specialist physiotherapy protocol compared
to treatment as usual on the following domains of
measurement:
1. The patient’s perception of change in their
functional motor disorder
2. Level of mobility
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3. Health-related quality of life
4. Employment and return to work
5. Objective measures of health service use
6. Subjective measures of health service use
7. Understanding and illness beliefs
8. Anxiety and depression
9. Satisfaction with treatment
10. Confidence that the diagnosis of FMD is correct
11. The influence of the number of somatic symptoms
reported at baseline on treatment outcome
In addition, the cost-effectiveness of specialist physio-
therapy compared to treatment as usual will be evalu-
ated in a comprehensive health economic analysis.
Methods and design
Trial design
The study design is a pragmatic, UK multicentre, single-
blind, parallel group RCT in adults with FMD. The trial
will compare a specialist physiotherapy protocol with treat-
ment as usual, which is defined in the trial as a referral to a
community physiotherapy service suitable for people with
neurological symptoms. Participants are randomised with a
1:1 ratio to either treatment arm and will be assessed at
baseline (pre-randomisation), 6 and 12months post-
randomisation. The primary outcome is assessed at 12
months. The trial flowchart is presented in Fig. 1.
Participants
The target population is adults with a “clinically definite”
diagnosis of functional motor disorder [15].
Recruitment
The neurologists signed up to the trial will screen outpa-
tients and inpatients (due to be discharged) who have
been referred to them. It is the responsibility of the neur-
ologist to determine a patient’s eligibility for the trial. As
per usual practice, the diagnosis of FMD will be explained
to the patient following a standardised method which em-
phasises the diagnosis based on positive clinical features,
potential for reversibility and that psychological comor-
bidity, if present, is not part of the diagnosis [16]. Patients
meeting the eligibility criteria will be informed about the
study by the neurologist and provided with a patient infor-
mation sheet. The neurologist will then seek agreement
from the patient to be contacted by a member of the re-
search team. Those willing to take part in the trial will be
invited to an appointment to provide informed consent
and complete baseline assessments before being rando-
mised to their treatment allocation.
Inclusion criteria
The inclusion criteria are:
1. New or returning patients presenting to
participating outpatient neurology clinics and
neurology inpatients.
2. The patient has a “clinically definite” diagnosis of
FMD according to the Gupta and Lang diagnostic
classification criteria [15].
3. Age 18 or over.
4. Diagnostic investigations have come to an end.
5. The patient is accepting of the intervention.
6. Motor symptoms must be sufficient to cause
significant distress or impairment in social,
occupational or other important areas of
functioning (subjectively described by the patient),
independent of other comorbidities.
Exclusion criteria
Participants will be excluded from the trial if:
1. The recruiting neurologist deems the patient to
have severe psychiatric comorbidity, including
factitious disorder, self-harm, anxiety and depres-
sion, which would interfere with the patient’s ability
to participate in physiotherapy.*
2. The patient has an organic diagnosis which explains
the majority of their symptoms or disability.
3. The patient has pain, fatigue or dissociative seizures
that would interfere with their ability to engage in
the trial physiotherapy intervention.**
4. Disability to the extent that the patient requires
assistance for toileting.
5. The patient is unable to attend 9 sessions of
physiotherapy over a 3-week period, within 6 weeks
of their initial neurology consultation.
6. Ongoing unresolved compensation claim or
litigation.
7. The patient has no fixed address or is seeking
rehousing through their council for disability access
reasons.
8. Unable to understand English sufficiently to
complete questionnaires.
9. The patient has a documented learning disability
that prevents them from answering questionnaires
independently.
10. The patient lacks capacity to give consent.
* The decision to exclude a patient due to psychiatric
comorbidity is a clinical decision made by the neurolo-
gist, rather than a decision based on a screening tool or
questionnaire. We believe that no single screening tool
or questionnaire would serve this purpose. Additionally,
there is insufficient data on which to base cut-off scores
to exclude patients on any particular questionnaire.
** Pain, fatigue and dissociative seizures are not abso-
lute exclusions. Based on previous research we expect
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most participants to experience persistent pain and fa-
tigue to various degrees. The participant is only excluded
if these symptoms are judged to be likely to prevent
them from engaging with the intervention.
Interventions
Specialist physiotherapy (intervention group)
Participants in this group will receive a protocolised, spe-
cialist physiotherapy programme that has been designed
based on a specific and novel biopsychosocial understand-
ing of FMD [17, 18]. This understanding emphasises the
role of self-focused attention in driving symptoms and this
is addressed as part of the intervention by (i) helping the
patient to understand the role of attention and; (ii) move-
ment retraining with an external focus of attention (impli-
cit motor learning). These are important ways in which
the intervention differs from typical neurorehabilitation,
which usually involves explicit motor learning strategies
and exercises that encourage attention to be directed
towards movement and sensations. See Table 1 for a
description of the intervention following the TIDIER
framework [19]. The intervention is also based on pub-
lished consensus recommendations for physiotherapy
treatment of FMD [13]. The key elements of the interven-
tion are (i) symptom education; (ii) movement retraining
with redirection of the patient’s focus of attention; and
Fig. 1 CONSORT flow diagram
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Table 1 Physio4FMD Intervention description following the TIDIER checklist
1. Name Provide the name or a phrase that describes the intervention.
Physio4FMD: Specialist physiotherapy for functional neurological disorder.
2. Why Describe the rationale, theory, or goal of the elements essential to the intervention.
The rationale for the Physio4FMD treatment is primarily based on a particular aetiological model for FMD [18]. The model
highlights two key mechanisms that drive functional motor symptoms. These are:
1. Functional motor symptoms require the patient’s attention, at a level without voluntary control, to be directed towards their
body in order to manifest. When the patient’s attention is distracted, the movement disorder disappears or dampens.
2. The patient has an expectation, at a level without voluntary control, that their movement will be abnormal; this expectation
is associated with a particular illness belief (e.g. my legs are paralysed). Expectations of abnormal movement influence motor
output with symptoms arising as a ‘habit’ that the nervous system has got in to.
The Physio4FMD intervention addresses attention-related movement problems by retraining activity (movement) while redirecting
the patient’s focus of motor attention. Altered expectations and illness beliefs are addressed through education, demonstrating to
the patient that they can move normally and helping the patient to develop strategies that normalises their movement during
every day activities.
The essential elements of the intervention are:
1. Prior to physiotherapy, the participant receives a diagnosis of FMD by a neurologist. The neurologist gives a thorough
explanation of FMD and how the diagnosis was made positively based on clinical features, and not as a diagnosis of exclusion.
2. Education about FMD, following which the participant and physiotherapist collaboratively devise a formulation to theorise
how the patient developed their movement problem using the aetiological model as a framework [9].
3. Education about common problems associated with FMD (persistent pain, fatigue and memory/concentration problems).
4. Movement and posture retraining, with the participant’s focus of attention directed away from their body (areas addressed
include sitting postures, sit to stand, walking, getting on and off the floor, stairs, upper limb problems, and use of walking aids).
5. Developing a self-management plan (which includes understanding medication, addressing boom-bust patterns of activity,
how to incorporate movement strategies into daily routine, self-management goals, and managing symptom exacerbations
and relapses).
3. What: Materials Describe any physical or informational materials used in the intervention, including those provided to participants or used in
intervention delivery or in training of intervention providers. Provide information on where the materials can be accessed (such as
online appendix, URL).
Information for Neurologists, document: Each trial neurologist will receive a document summarising their role in the trial, which
includes an explanation of how to apply the eligibility criteria, how to explain FMD to patients, how to discuss the trial with
potential participants, and requirements for follow up.
Patient Workbook: Each intervention participant is given a workbook, which guides the intervention. The workbook is completed
by both the participant and the physiotherapist during treatment. Key sections of the workbook are: (i) understanding the
diagnosis; (ii) neuroanatomy and physiology; (iii) pages for participants to reflection on sessions; (iv) analysis and exploration of
movement; (v) movement retraining; (vi) understanding problems associated with FMD (pain, fatigue and memory problems); and
(vii) self-management plan. Amongst other goals, the workbook helps to standardise the intervention.
Physiotherapy Intervention Manual: Each physiotherapist providing the trial intervention will receive an intervention manual that
complements the Physio4FMD training programme.
4. What:
Procedures
Describe each of the procedures, activities and/or processes used in the intervention, including any enabling or support activities.
Neurology: Prior to enrolling in the trial, participants in both groups are seen by one of the study neurologists. The diagnosis of
FMD is made and explained to the patient following a standardized explanation [16]. Participants in both arms of the trial will be
followed up by their neurologist at least once within 12 months of their initial neurology consultation.
Physiotherapy – Education: Participants receive a standardised explanation of FMD using the workbook as a guide. This is followed
by an individualised formulation, where the participant and physiotherapist collaboratively devise a theoretical explanation for
how the person came to develop FMD, using a symptom model [9]. The formulation seeks to determine relevant risk factors,
triggers, initial symptoms, examples of attention affecting movement, adaptive coping strategies, secondary changes, and social
factors. Education includes information about some common problems associated with FMD (pain, fatigue, and memory/
concentration).
Physiotherapy – Movement Retraining: Movement retraining generally follows a sequential motor learning approach, building up
desired movement patterns starting from elementary, symptom free components of movement [13]. Problematic movement
patterns and tasks are identified in the initial assessment; only those relevant to individual are retrained. The workbook prompts
exploration and practice of 7 key tasks (i) sitting postures, (ii) sit to stand, (iii) standing and walking, (iv) arm and hand problems,
(v) use of walking aids, (vi) getting on and off the floor, and (vii) using stairs.
Movement retraining is tailored to the individual, but should adhere to the key principle of employing strategies that redirect the
patient’s focus of motor attention. In practice this is achieved by:
• Asking the patient to focus on the goal of the task rather than the mechanics of movement
• Practice movements in front of a mirror (the patient focus of attention is redirected externally to their reflection)
• Redirecting the patient’s focus to an another part of their body or a specific component of the movement
Specific exercises and activities to retrain movement that conform to the above principles are suggested in the intervention man
ual and have been published elsewhere [13]. If available, the physiotherapist may choose to use the following standard
physiotherapy adjuncts: electrical muscle stimulation, treadmill, other exercise equipment.
Physiotherapy – Personal Reflections: At the end of each physiotherapy session, the participant is encouraged to write a reflection
in their workbook, addressing several prompts. The subsequent session starts by reviewing the reflection of the previous session
and discussing any questions or issues that arise. After which, a plan is made for the current session.
Physiotherapy – Self-Management: To conclude treatment, a personalised self-management plan is developed, which usually
includes: (i) a summary of useful strategies that help to normalise movement; (ii) activity plans to address boom and bust pat
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(iii) developing a long term symptom management plan.
The intervention is delivered over 9 sessions within a 3-
week period, plus a 3-month follow up session. Two ses-
sions may be scheduled in 1 day if separated by a break.
Flexibility is allowed in the arrangement of sessions over
the 3 weeks to accommodate other commitments of the
patient and physiotherapist.
The intervention is guided by a workbook that is com-
pleted by both the patient and physiotherapist during ses-
sions and the patient is encouraged to write a reflection at
Table 1 Physio4FMD Intervention description following the TIDIER checklist (Continued)
terns and how to progress activity; (iii) future goals; and (iv) what to do on difficult days and during periods of symptom
exacerbation.
5. Who provided For each category of intervention provider, describe their expertise, background and any specific training given.
Neurologists: All neurologists involved in the trial will be employed at a consultant level at one of the trial sites. Only
neurologists with a clinical interest and experience in treating patients with FMD will be invited to participate. They will
receive training from one of the research neurologists (ME or JS) in person or by telephone, lasting 30–60 min. The training
topics are listed in item 3 above. This information will be supplemented with written information.
Physiotherapists: The intervention physiotherapists will have at least 2 years’ experience working in the field of neurological
physiotherapy. Each will undergo 1 week full time training, delivered by the research physiotherapists (GN and KH).
Competency will be assessed according to a checklist that ensures the physiotherapist has demonstrated an understanding or
proficiency in delivering the key ingredients of the intervention. They will also receive a comprehensive intervention manual.
During delivery of the intervention, each physiotherapist will receive supervision over telephone from one of the research
physiotherapists. At least one supervision session will be planned for every intervention participant treated.
6. How Describe the modes of delivery (such as face to face or by some other mechanism, such as internet or telephone) of the
intervention and whether it was provided individual or in a group.
Each session is conducted face to face and individually (there are no group treatment sessions).
7. Where Describe the type(s) of location(s) where the intervention occurred, including any necessary infrastructure or relevant features.
Participants will be recruited from inpatient or outpatient neurology clinics. The physiotherapy sessions will be held in a
physiotherapy gym or clinic with space suitable for movement and gait retraining and space suitable for education and
writing in the intervention workbook. The only essential equipment is a full-length mirror. Physiotherapists can make use of
other standard therapeutic equipment as appropriate (e.g. treadmill, electrical muscle stimulation device, other exercise
equipment).
8. When and how
much
Describe the number of times the intervention was delivered an over what period of time including the number of sessions,
their schedule and their duration, intensity or dose.
The physiotherapy intervention is delivered over 9 sessions, which should be completed within a 3-week period. There is also
a 3-month follow up session. Each session should last between 45min and one hour. It is permissible to schedule 2 sessions in
1day, separated by a (lunch) break. Home exercise programmes are not usually part of the intervention. Instead, the patient is
encouraged to incorporate movement strategies and plans (e.g. activity plan to avoid boom and bust patterns) into their
normal daily routine.
9. Tailoring If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when and how.
The intervention is standardised by following a workbook; however, only information and tasks relevant to the individual’s
problem will be addressed. Movement retraining focuses on 7 key tasks, which are described in item 4 above. When retraining
each task, strategies are adapted and personalised for the individual, but the approach should adhere to the key principle of
redirecting the participant’s attention away from their movement or body. Passive interventions such as massage and
acupuncture are discouraged.
10. Modifications If the intervention was modified during the course of the study, describe the changes (what, why, when, and how).
Not applicable.
11. How well:
Planned
If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or
improve fidelity, describe them.
Fidelity of the intervention will be assessed in the following ways.
(i) At the level of the physiotherapist: The physiotherapist providing the trial intervention will complete a treatment checklist
(paper form) for each participant, which conforms to the TIDIER intervention description.
(ii) At the level of the participant: We will monitor the content, length and number of physiotherapy sessions by participant
report for both trial arms with a structured telephone survey. The interview will also assess for contamination between the
groups.
(iii) Fidelity of the trial intervention will also be assessed by evaluating a random sample of completed intervention workbooks.
The workbook guides the intervention and is filled in during the treatment session by both the participant and
physiotherapist. It therefore provides a record of the content of sessions. Fidelity will be judged against predefined criteria. We
aim to assess 40% of the intervention workbooks.
12. How well:
Actual
If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as planned.
Not applicable.
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the end of each day. The intervention starts by taking a
full history from the patient and completing a physical as-
sessment. This is followed by education about FMD ac-
cording to a specific biopsychosocial aetiological model
[9]. The patient and physiotherapist then collaboratively
devise a formulation to theorise how the patient developed
their movement problem using the biopsychosocial model
as a framework [9]. It takes into account risk factors, trig-
gering events, psychological factors (such as panic at on-
set), self-focused attention disrupting normal movement,
and secondary problems (such as unhelpful reinforcement
of symptomatic movement patterns). Movement retrain-
ing mostly occurs within the context of tasks such as
standing up, sitting down, walking, drinking from a cup,
etc. It generally follows a sequential motor learning ap-
proach, where elementary symptom-free components of
movement are established and then built upon in succes-
sive stages to reshape normal movement patterns. Strat-
egies that normalise movement (for example, redirecting
the patient’s focus of motor attention away from the body)
are incorporated into movement retraining. Examples of
such strategies have been described in detail elsewhere
[13]. Movement retraining is practised and progressed
over the remaining sessions, interspersed with information
about managing pain, fatigue and concentration problems,
if they are relevant to the individual. A long-term self-
management plan is completed in the workbook in the
final sessions. The 3month follow up session is an oppor-
tunity to review and update the self-management plan, as
well as to provide encouragement and reassurance.
The physiotherapists delivering the trial-intervention
will have at least 2 years’ experience working in neuror-
ehabilitation. They will receive a manual describing the
intervention and will undergo a comprehensive training
programme delivered over 5 consecutive days. They will
also receive a supervisory phone call from an experi-
enced member of the trial team for each participant
treated in the trial, which aims to provide clinical
support, as well as ensuring fidelity with the trial
intervention.
Treatment as usual physiotherapy (control group)
The control arm of the trial is “treatment as usual”,
which, for the purposes of this trial, is a referral to a
community physiotherapy service appropriate for pa-
tients with neurological symptoms. The referral letter to
physiotherapy will come from the diagnosing neurolo-
gist. It will state the diagnosis and that the patient may
benefit from physiotherapy treatment. The referral letter
will be accompanied by a copy of the patient’s neurology
consultation letter.
We will monitor the content of the control physiother-
apy arm via participant report in a telephone survey.
There are no formal evidence-based guidelines for
physiotherapy for FMD, therefore the treatment received
by the control participants will be variable. Based on the
preceding feasibility trial we expect that most physio-
therapists will provide a combination of gait retraining,
stair practice, balance, non-specific cardiovascular exer-
cise, specific strengthening exercises, stretching, and
provision of walking aids or splints. The frequency and
number of physiotherapy sessions provided by commu-
nity therapy services will differ between centres, accord-
ing to local policies. In addition, some trial participants
may also be offered treatment from occupational therapy
and/or clinical psychology, although in our feasibility
trial we found that this was rare. Additional treatments
such as these will be recorded at the 6 month and 12
month data collection (via the patient self-complete Cli-
ent Service Receipt Inventory).
We anticipate that, in general, the intervention will
differ from the control treatment in the following ways:
(i) greater emphasis on education using a specific
aetiological model; (ii) movement retraining will focus
on redirecting attention away from the movement; (iii)
greater emphasis on self-management; (iv) greater num-
ber of sessions; (v) higher intensity or frequency of ses-
sions; (vi) use of FMD specific written materials (i.e.
workbook); (vii) acknowledging and addressing coexist-
ing problems (i.e. pain, fatigue, and concentration). We
will examine these assumptions in a post-treatment tele-
phone survey of participants from both groups.
Both groups
Participants in both arms of the trial will be followed up
by their neurologist at least once within 12 months of
their initial neurology consultation as part of standard
NHS care.
To encourage retention, we will reimburse the cost of
travel to research appointments and physiotherapy treat-
ment, up to the value of £25 per appointment.
Outcome measures
Outcome measures will be collected at 6 and 12months’
post randomisation. The primary outcome is the Physical
Function domain of the SF36 questionnaire [20, 21], mea-
sured at 12months post randomisation. The secondary
outcome measures and timing of data collection are listed
in Table 2.
Hospital Episode Statistics (HES) covering acute hos-
pital care (inpatient and outpatient attendances) from
NHS Digital and the equivalent data from NHS Scotland
(eDRIS) will be used as an objective (non-patient re-
ported) measure of change, comparing the difference be-
tween groups at 12 months, adjusting for baseline data.
The Extended Patient Health Questionnaire-15 (PHQ-
15) [31, 32] will be collected at baseline only. This data
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will be used to explore the relationship between somatic
symptoms reported at baseline with outcome.
Other demographic and clinical data
At baseline we will collect a range of data to describe
the study population. Demographic information will in-
clude: age, gender, ethnicity, marital status, living ar-
rangements, dependents, education, and employment
status. Clinical information will include: symptom
phenotype, symptom duration, past medical history, and
previous treatments. Information about adverse events
will be collected systematically during a post-treatment
telephone assessment and the self-complete 6 and 12
month follow up assessments. Participants are also
instructed to inform the trial team about adverse events
as soon as possible as they occur. The schedule of data
collection is displayed in Table 3.
The fidelity of the intervention will be assessed in the
following ways:
(i) Both groups: We will monitor the provision of
physiotherapy in both groups by participant report
with a structured telephone survey. Participants will
be surveyed by a nonblinded member of the
research team as soon as possible after completing
treatment. The survey will explore the content,
number and length of physiotherapy sessions, as
well as the participant’s satisfaction with their
allocated treatment.
(ii) Intervention group: The physiotherapist providing
the study intervention will complete a treatment
checklist (paper form) for every participant,
recording the content of each session. The checklist
is based on the TIDIER checklist description of the
intervention, (see Table 1) [19].
(iii) Intervention group: We will assess a random
sample of intervention workbooks. The workbook
guides the intervention and is completed during the
treatment session by both the participant and
physiotherapist. It therefore provides a record of
the content of sessions. Two workbooks will be
randomly selected from every 5 participants treated
by each intervention physiotherapist (40% of
intervention participants). The workbooks will be
assessed against a predetermined set of criteria to
determine the extent to which treatment followed
the intervention protocol.
Sample size calculation
The power calculation was based on data from the pre-
ceding single centre randomised feasibility trial [12], in
which, at 6 months follow up we found a between
groups difference of 19.8 in the SF36 Physical Function
domain in favour of the intervention group (after adjust-
ing for baseline differences). A treatment effect is likely
to be smaller in a pragmatic multicentre trial; we there-
fore aim to detect a 9 point difference in the SF36 Phys-
ical Function domain, which we consider to be a
clinically important difference.
In order to detect a 9 point difference in the SF36
Physical Function domain at the 5% level of significance
with 90% power, we require 264 participants, 132/group.
The calculation used the ANCOVA method with one
pre and one post randomisation measurement, assuming
a standard deviation of 22, which gave an estimated
sample size of 75/group. The sample size was inflated to
Table 2 Outcome Measures
Assessment Domain of measurement Timing
T0 T1 T2
Physical Function domain, SF36 [21] Physical disability X X X
Short Form 36 (SF36) [20] Health related quality of life X X X
Functional Mobility Scale [22] Mobility related disability X X X
Revised Illness Perception Questionnaire [23] Illness belief and understanding X X X
Hospital Anxiety and Depression Scale [24] Anxiety and Depression X X X
Clinical Global Impression Scale of Improvement (CGI-I) [25] Patient perception of change X X
Fatigue (5-point scale) [26] Fatigue X X X
EQ-5D-5 L [27] Health Economics, to generate QALYS X X X
Client Service Receipt Inventory (CSRI) [28] Health Economics, health resource use X X X
Work Productivity & Activity Impairment Questionnaire (WPAI) [29] Employment and return to work X X X
Confidence in correctness of diagnosis of FMD (10 point scale) [30] Illness belief, confidence in diagnosis X X X
Extended Patient Health Questionnaire-15 (PHQ-15) [31, 32] Somatic symptom severity X
Hospital Episode Statistics (HES) Health Economics, health resource use X X
Abbreviations: T0 Baseline assessment, T1 6-month assessment, T2 12-month assessment, QALYS Quality Adjusted Life Years. Pain is assessed as part of the SF36
and EQ-5D-5L questionnaires
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account for therapist effect (clustering) in the interven-
tion arm, assuming eight therapists. We assumed the
average number of participants treated by physiothera-
pists delivering the trial intervention (cluster size) will be
9 after 20% drop out. The resulting inflation factor was
1.4, which we applied to both groups to give equal group
sizes of 105/group. The sample size was then inflated by
a factor of 1.25 to account for a 20% dropout rate.
Randomisation and blinding
Randomisation will be conducted by the Trial Manager
using a remote web-based application, Sealed Envelope
[33], and will be overseen by a clinical trials unit (UCL
Priment). Randomisation will occur at the level of the
participant, stratified by site. Block randomisation with
random block sizes will be used to ensure even alloca-
tion of intervention and control participants across sites.
The researchers collecting outcome data, the statisti-
cians and health economists will be blind to treatment
allocation. The Trial Manager, participants and treating
clinicians will not be blinded due to practical reasons.
Statistical analysis
An intention to treat analysis will be conducted after the
database is locked following collection of final 12month
follow up data. The primary outcome, the SF36 Physical
Function domain, will be analysed using random effects
modelling, with therapist as the random effect (individuals
for those in the control group), controlling for baseline
scores. The Clinical Global Impression Scale will be col-
lapsed into two groups, good outcome and poor outcome.
Good outcome will be defined as ratings of “much im-
proved” or “improved” and poor outcome will be defined
as rating of “same”, “worse”, or “much worse”. This will be
analysed using random effects logistic regression. Other
clinical secondary outcomes will be analysed as for the pri-
mary outcome. We will perform sensitivity analyses look-
ing at the effect of missing data, additional interventions
received (e.g. psychology) and dose-response relationship
for the control and intervention conditions.
We aim to complete an exploratory analysis of prog-
nostic indicators. This will use random effects logistic
regression modeling to determine predictors of a good
or bad outcome from baseline demographic and clinical
Table 3 Schedule of data collection
Study Procedures Face-to-face assessment Post
Treatment
telephone
call
Telephone, mail or online
form assessment*
Screening & Baseline Assessment 6 Months 12 Months
Informed consent ✓
CRF Inclusion/exclusion criteria ✓
Medical history ✓
Demographics ✓
Clinical characteristics ✓
Assessments Short Form 36 ✓ ✓ ✓
Functional Mobility Scale ✓ ✓ ✓
Revised Illness Perception Questionnaire ✓ ✓ ✓
Hospital Anxiety & Depression Scale ✓ ✓ ✓
Client Service Receipt Inventory ✓ ✓ ✓
EQ-5D-5 L ✓ ✓ ✓
Work Productivity & Impairment Questionnaire ✓ ✓ ✓
Clinical Global Impression Scale (CGI-I) ✓ ✓ ✓
Fatigue State ✓ ✓ ✓ ✓
Confidence in correctness of diagnosis ✓ ✓ ✓
Extended Patient Health Questionnaire-15 ✓
Randomisation ✓
Adverse events screen ✓ ✓ ✓
Satisfaction with intervention Questionnaire ✓
Participant description of intervention ✓
HES data obtained from NHS Digital and eDRIS services covering the
previous 18months
✓
*6 and 12 month follow up assessments will be completed by the participant's preferred option out of telephone, mail or online form
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characteristics. Outcome will be determined by a self-
rating of “improved” or “much improved” on the CGI-I
scale and a 10 point increase in SF36 Physical Function
domain score. This analysis will be indicative, and any
factors which appear to be associated with the outcome
will need further investigation in a study that is powered
for that purpose.
Health economic analysis
The aims of the health economic evaluation will be two-
fold: (i) To estimate the cost impact of the Specialist
Physiotherapy protocol compared to treatment as usual
for FMD over 12 months, firstly from a health and social
care cost perspective and secondly from a societal per-
spective. (ii) Calculation of Quality Adjusted Life Years
(QALYs) over 12 months from responses to the EQ-5D-
5 L and calculated as the area under the curve adjusting
for baseline [34]. This will be used to calculate the mean
incremental cost per QALY gained with the specialist
physiotherapy protocol compared to treatment as usual
over 12 months. Bootstrapping will be used to construct
confidence intervals, cost-effectiveness planes and cost-
effectiveness acceptability curves. Sensitivity analyses will
be conducted to test the impact of any assumptions
made as part of the analysis. The primary health eco-
nomic analysis will be from a health and social care cost
perspective with a secondary analysis to account for the
impact on employment from a societal perspective. Simi-
lar to the analysis of the primary outcome, we will use
random effects modelling for the therapist effect.
An adapted version of the Client Service Receipt In-
ventory (CSRI), informed by our experience of using this
questionnaire in the feasibility trial, will be used to col-
lect resource use and employment information. The
Work Productivity & Activity Impairment Questionnaire
will be used to calculate the cost impact of improved en-
gagement with employment as a result of being rando-
mised to specialist physiotherapy. Productivity will be
costed using the human capital approach. Other re-
source use will be costed using nationally published
sources including the Personal and Social Services Re-
search Unit [34], British National Formulary [35] and
National Reference Costs [36].
For the HES data, we will report descriptive statistics
for each service type (outpatient, A&E, inpatient) separ-
ately. Suitable descriptive statistics and statistical tests
will be selected for each service type depending on the
distribution of the data (i.e. non parametric tests for
highly skewed data). We will include an analysis using
general linear models (GLM) and appropriate family and
log links to account for the distribution of the data. The
GLM models will be used to calculate differences in ser-
vice use between trial arms, adjusting for baseline service
use. HES data will also be used to validate the results of
the analysis of secondary/hospital care service use re-
ported in the CSRI. The data will include information
on Healthcare Resource Groups for inpatient HES data
and diagnostic and procedural codes for all other data
and will be costed using the National Reference Costs
[36]. The CSRI analysis will be validated with the HES
data by (i) applying more specific costs based on reason
of attendance; (ii) checking the reliability of patient
reporting; and (iii) investigating the implications for the
cost-effectiveness analysis by including HES data for par-
ticipants with missing data or for those lost to follow up.
Data handling and monitoring
The trial will be overseen by and run according to the
Priment Clinical Trials Unit standard operating proce-
dures, ensuring the trial complies with Good Clinical
Practice and maintains scientific integrity. The Trial
Manager will monitor the accuracy of data entry
throughout the trial and undertake source verification
checking against paper records.
Baseline data and questionnaires will be collected on
paper case report forms and entered into a web-based
data management system, Sealed Envelope [33]. The 6
and 12month assessments will be completed by partici-
pants according to their preferred method, either an on-
line form, paper form, or with support from a research
assistant over telephone. A non-contingent gift voucher
will be sent to participants prior to 6 and 12month data
collection to encourage participation and minimise miss-
ing data (£10 at 6-months, £15 at 12-months).
Trial oversight committees will be set up according
the requirements of the funder. A Trial Management
Group, consisting of the grant holders, trial statistician
and health economist and two patient and public repre-
sentatives will meet regularly to monitor the conduct of
the trial. An independent Trial Steering Committee
(TSC) will meet six monthly to oversee the conduct of
the trial. The TSC will be chaired by an independent re-
search expert and consist of a statistician, health econo-
mist, an expert clinician and 2 patient and public
representatives. An independent Data Monitoring and
Ethics Committee (DMEC), consisting of two expert cli-
nicians and a statistician will meet 6 monthly to review
trial data and safety related issues/adverse events. The
DMEC will advise the TSC.
Ethical approval
Ethics approval was obtained from the London-Surrey
Borders Research Ethics Committee, reference number
18/LO/0486. Approval was granted 28 March 2018.
Local NHS approvals are being obtained prior to open-
ing each trial site.
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Discussion
To our knowledge, this will be the first adequately pow-
ered, parallel group design RCT of physiotherapy or
physical rehabilitation for FMD. The trial compares a
protocolised specialist physiotherapy intervention with
treatment as usual. The primary outcome is physical dis-
ability at 12 months post randomisation, as measured by
the SF36 Physical Function domain. We will also assess
a range of secondary outcomes and complete a compre-
hensive health economic analysis.
We support the choice of our primary outcome be-
cause the SF36 Physical Function domain has been
found to be a valid measure of physical and mobility re-
lated disability [21]. While it is a self-report measure, it
asks respondents to report limitations on their ability to
carry out particular activities rather than the level of dis-
tress associated with these. The physical functions sam-
pled include vigorous activities (such as participating in
strenuous sports); moderate activities (such as pushing a
vacuum cleaner); carrying groceries; climbing stairs;
walking 100 yards/several hundred yards/more than a
mile; and bathing or dressing. Poor Physical Function
domain scores have been found to be related to low
scores of physical performance tests such as low grip
strength and longer Timed Up and Go test scores [21].
Our trial has a pragmatic design, in that it is con-
ducted and contained within the real-world limitations
of NHS pathways. The results of pragmatically-designed
trials are considered to have greater generalisability than
research conducted under highly controlled ideal condi-
tions [37]. The pragmatic nature of our trial has implica-
tions that are both strengths and limitations of the trial
design. One limitation of our pragmatic design is the
‘treatment as usual’ control condition. In the NHS there
are no formal evidence-based guidelines for the treat-
ment of FMD; therefore, we expect large variations in
the number of sessions and the content of physiotherapy
treatment received by control participants. We will
monitor the provision of control physiotherapy (by par-
ticipant report), and in the post hoc analysis we will
explore the impact of the number of sessions received
by control participants on treatment outcome. We con-
sidered trying to standardise the control intervention;
however, this was not possible within our budgetary
constraints.
The pragmatic nature of our trial gives rise to a num-
ber of design strengths. We have a relatively relaxed eli-
gibility criteria that reflects the heterogeneity of people
with FMD. Although we expect that only 25–30% of pa-
tients with FMD are suitable for a physiotherapy-led
intervention (and will therefore meet our eligibility cri-
teria), we have no restrictions on phenotype, age or
symptom duration. The intervention is delivered within
current NHS services by clinicians who would normally
be involved with this patient group. Thus our outcomes
should be considered generalisable.
The outcome measures are largely patient-reported
subjective outcomes (with the exception of the HES data
(Hospital Episode Statistics, linked to individuals), which
will be reported for each participant and will be used to
compare episodes of NHS care pre- and post-treatment).
Objective measurement of symptoms and disability in
FMD is a complex issue. Snapshot tests (such as dyna-
mometry, gait speed, and movement disorder severity)
have questionable reliability and validity as physical
examination, is by definition, internally inconsistent in
patients with FMDs [38, 39]. This is related to the mech-
anistic role of self-directed attention in driving the
motor symptoms [18]. Arguably, subjective report could
therefore be considered a more valid measure of disabil-
ity and distress in FMD. Reliance on patient reported
outcomes allows for less obtrusive remote assessments
(via web-based forms and post), which in turn may limit
the introduction of artificial aspects to outcome meas-
urement (e.g. the desire to please the clinician) [37]. To
support the battery of patient reported outcomes, we
will report and analyse NHS Digital data on episodes of
care. This non-patient reported and objective outcome
will be considered a proxy measure of improvement.
If the trial intervention proves to be clinically and cost
effective, there will be a strong argument in support of
commissioning specialist services for people with FMD,
and rolling out the intervention across the NHS. A posi-
tive result should also have an international impact, pro-
viding an impetus for the development of FMD services
beyond the UK. Although this is a trial of neurology and
physiotherapy treatment, the data gathered on the use-
fulness of the trial intervention may well have important
implications for the clinical practice of occupational
therapists, psychiatrists and psychologists working with
people with functional neurological disorder.
Trial status
Participant recruitment began on 15 November 2018
and is ongoing.
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